NRx’s COVID-19 Vaccine Candidate BriLife Impresses In Phase II
Promising Delta Variant Antibody Levels
NRx’s BriLife has demonstrated strong potential in early data from a mid-stage COVID-19 trial, spurring the company on to begin a Phase IIb/III study as soon as possible.
